Top 10 Blockbuster Drugs Going Generic in 2024

Developed by Novo Nordisk, Ozempic, an injectable GLP-1 analogue, has been a blockbuster drugs used as diabetes drug

January 25, 2024

861

Table of Contents

Last Updated on October 11, 2024 by The Health Master

Blockbuster Drugs

Blockbuster Drugs: In the realm of healthcare, the discovery and development of innovative medicines play a crucial role in finding treatment and addressing the burden of diseases.

However, the journey from discovery to market is not only lengthy but also incurs substantial costs. The cost of bringing a new drug to market is approximately $5 billion, and the process can take nearly 15 years.

Follow us on WhtasApp Channel

The Impact of Pharmaceutical Patents

When a pharmaceutical company develops a new drug, it is introduced to the market under a brand name and comes under patent protection.

These patents, while fostering innovation, also contribute significantly to the revenue of pharmaceutical companies. Studies suggest that patents account for roughly 80 percent of the overall revenue in this industry.

Global Trends

According to a report by Allied Market Research, the global patented drugs market size reached $814.4 billion in 2022 and is projected to surge to $1,456.5 billion by 2032, exhibiting a CAGR of 6.0% from 2023 to 2032.

The Impact of Patent Expirations

A 2018 report by EvaluatePharma highlighted a significant challenge in the pharmaceutical landscape.

As patents of key drugs expire between 2018 and 2024, there is a potential threat to wipe off branded drug sales worth $251 billion of global pharmaceutical companies.

In 2023, the widely-used drug Humira lost its patent, setting the stage for major changes in the industry.

Click for more Articles on Pharmaceuticals

Click for more Legal Articles on Pharmaceuticals

The Countdown: Top 10 Blockbuster Drugs Facing Patent Expiry in 2024

Abilify Maintaina Kit – A Schizophrenia Game-Changer

With a revenue of $15.5 billion in 2022, Abilify Maintaina from Otsuka Pharmaceutical is a long-acting injectable antipsychotic set to lose its patent by October 2024. Experts believe it will continue dominating the growing antipsychotic market.

XARELTO – Navigating Risks in Anticoagulation

Developed by Janssen Pharms, Xarelto, a top-selling drug in the anticoagulant market, is poised to lose its patent in August 2024. Widely used to reduce the risk of stroke and systemic embolism, its expiration opens the door for potential alternatives.

FARXIGA – Transforming Diabetes Care

AstraZeneca’s Farxiga, a blockbuster drugs used as anti-diabetic drug, faces patent expiry. Despite generating around $4.3 billion in annual sales, concerns about side effects like urinary tract infections linger.

Ozempic – Unveiling the Future of Diabetes Treatment

Developed by Novo Nordisk, Ozempic, an injectable GLP-1 analogue, has been a blockbuster drugs used as diabetes drug, with annual sales of around $3.6 billion. However, its patent is set to expire in May 2024.

Click for Guidance documents for industry

LYNPARZA – A Beacon in Cancer Treatment

AstraZeneca’s Lynparza, a PARP inhibitor for advanced ovarian, breast, and prostate cancers, generated $2.7 billion in sales in 2022. Its patent expiry in 2024 marks a potential shift in the landscape of cancer therapies.

SYMBICORT – Breathing Easier Until November 2024

Symbicort, a respiratory drug by AstraZeneca, has been a key player in asthma and COPD treatment since 2006. Losing its patent in November 2024 will reshape the pharmaceutical dynamics in this segment.

ENTRESTO – Navigating the Heart Failure Landscape

Developed by Novartis, Entresto, a major player in heart failure treatment, generated $2.5 billion in sales in 2022. Its patent expiry in May 2024 raises questions about the future of cardiovascular medications.

LATUDA – Illuminating Schizophrenia Treatment

Sunovion Pharmaceuticals’ Latuda, a crucial antipsychotic, recorded sales of around $1.8 billion in 2022. Its patent expiration in February 2024 prompts discussions on alternative treatment options.

XIFAXAN – Addressing Gastrointestinal Woes

Xifaxan from Salix Pharmaceuticals, an oral antibiotic for IBS-D and hepatic encephalopathy, faces patent expiry in June 2024. The pharmaceutical landscape in gastrointestinal diseases is set for transformation.

CABOMETYX – Revolutionizing Renal Cell Carcinoma Treatment

Exelixis’ Cabometyx, with sales of $1.4 billion in 2022, is approved for advanced renal cell carcinoma. Its patent expiration in September 2024 marks a potential shift in treatment approaches.

Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.

FAQs

Why do pharmaceutical companies patent their drugs?
- Pharmaceutical companies patent their drugs to protect their investment in research and development, giving them exclusive rights to sell the drug and recoup their costs.
How does the expiration of drug patents impact consumers?
- The expiration of drug patents can lead to the entry of generic versions, potentially lowering drug prices and increasing accessibility for consumers.
What happens when a drug loses its patent?
- When a drug loses its patent, other pharmaceutical companies can produce generic versions, leading to increased competition and potentially lower prices.
Are there risks associated with using generic versions of drugs?
- While generic drugs undergo rigorous testing for safety and efficacy, individual responses may vary. It’s essential for patients to consult their healthcare providers when considering a switch to generic medications.
How does patent expiry contribute to innovation in the pharmaceutical industry?
- Patent expiry encourages pharmaceutical companies to continuously innovate and develop new drugs, as the expiration allows for increased competition and the introduction of alternative treatments.